Continued Improvement in Survival of Multiple Myeloma Patients: An Institutional Study from 1992-2016
Multiple myeloma (MM) represents 1.8% of all new cancer cases in the U.S. While not curable, advances in treatment, including autologous stem cell transplant (ASCT) and maintenance therapy, have dramatically improved progression free survival (PFS) and overall survival (OS). The Ohio State University began utilizing ASCT for newly diagnosed MM (NDMM) patients in 1992. With the introduction of new, more effective drugs used before and after ASCT over time, we performed retrospective survival analysis in NDMM patients receiving ASCT from 1992-2016.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Jordan Nunnelee, Qiuhong Zhao, Don M. Benson, Ashley Rosko, Maria Chaudhry, Naresh Bumma, Abdullah Khan, Srinivas Devarakonda, Yvonne A. Efebera, Nidhi Sharma Tags: 336 Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Hematology | Jordan Health | Middle East Health | Myeloma | Stem Cell Therapy | Stem Cells | Study | Transplants